Our review of the literature reveals encouraging results, with a significant number of AITL patients responding to azacytidine treatment, underscoring its potential as a viable treatment approach given the prevalent TET2 mutation in AITL. The gene discussed is TET2; the disease is angioimmunoblastic T-cell lymphoma.